GSK Clinical Trials: 3,989 Led Studies

Archive historyOct 2022 to Jun 2026

103 recorded changes across GSK trials

Every status move, completion date shift and enrollment change ComplyRx has recorded across 26 of these trials. One is shown below.

Enrollment changeEnrollment reduced to 305 from 392NCT06796907 · recorded 1 Jun 2026

Track to read them

+99 more recorded changes · Track a drug to see every change the night it lands

Track pembrolizumab

Most active programmes

The drugs appearing most often across GSK's recently active trials. Comparator arms are excluded.

Belantamab mafodotin10 trials
Dostarlimab8 trials
Bepirovirsen7 trials
Depemokimab6 trials
Dexamethasone5 trials
Pembrolizumab5 trials

Upcoming readouts

Next primary completion dates among GSK's active phase 2 and phase 3 trials. Dates are registry estimates and move often, which is exactly what the tracker watches.

Oct 2026A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and …Phase 3
Dec 2026A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and …Phase 3
Dec 2026A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSm…Phase 2
Jan 2027A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-…Phase 3
Mar 2027BALANCE: A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With …Phase 2
May 2027A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With BronchiectasisPhase 2

Top therapeutic areas

Conditions studied most often across GSK's recently active trials.

HIV Infections10 trials
Asthma9 trials
Multiple Myeloma9 trials
Hepatitis B5 trials
Ovarian Neoplasms4 trials
Lung Cancer, Non-Small Cell4 trials

GSK trials

The 50 most significant of GSK's recently active trials, soonest estimated readout first.
Select any row for the full record; the change timeline unlocks with tracking.

Trial	Phase	Stability	Status	Enrollment	Est. readout
Mass Balance and Absolute Oral Bioavailability of [14C]VH4524184NCT07636928VH4524184	Phase 1	Not yet scored	OngoingRecruiting	9 est.	20 Aug 2026
Drug-Interaction Assessment of GSK3772701 in Healthy Male and Female Participants Aged 18 to 55 YearsNCT07670377Midazolam (MDZ)	Phase 1	Not yet scored	OngoingNot yet recruiting	20 est.	27 Aug 2026
A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202NCT06062420Dostarlimab	Phase 2	Locked · track to reveal	OngoingActive, not recruiting	316 est.	1 Sept 2026
A Study to Assess the Safety and Pharmacokinetics of a Human Monoclonal Antibody (VH4527079) in Healthy Adults and Persons With HIVNCT06652958VH4527079	Phase 1	Locked · track to reveal	OngoingActive, not recruiting	102 est.	9 Sept 2026
OCEANEfficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)NCT05263934Depemokimab	Phase 3	Locked · track to reveal	OngoingActive, not recruiting	163 est.	29 Sept 2026
LLSATLinerixibat Long-term Safety, and Tolerability StudyNCT04167358Linerixibat	Phase 3	Locked · track to reveal	OngoingActive, not recruiting	242 est.	30 Sept 2026
A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTpa) in Healthy Japanese Adolescents Aged 11 Years to <13 YearsNCT07596173dTpa vaccine	Phase 3	Locked · track to reveal	OngoingRecruiting	85 est.	14 Oct 2026
A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung CancerNCT05565378Pembrolizumab	Phase 2	Locked · track to reveal	OngoingActive, not recruiting	351 est.	9 Nov 2026
A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in AdultsNCT07464314Investigational mRNA Seasonal Flu/COVID-19 Combination (Flu/COVm) Vaccine	Phase 1	Locked · track to reveal	OngoingRecruiting	225 est.	3 Dec 2026
A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTpa) in Japanese Healthy Pregnant WomenNCT07596199dTpa	Phase 3	Locked · track to reveal	OngoingRecruiting	95 est.	11 Dec 2026
Extended Access of Momelotinib in Adults With MyelofibrosisNCT03441113MMB	Phase 2	Locked · track to reveal	OngoingActive, not recruiting	237 est.	11 Dec 2026
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib StudyNCT04641247Niraparib	Phase 2	Locked · track to reveal	OngoingRecruiting	37 est.	28 Dec 2026
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With AsthmaNCT05757102FF/UMEC/VI	Phase 3	Locked · track to reveal	OngoingRecruiting	292 est.	22 Jan 2027
ENTRANCEA Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIVNCT07053384VH3810109	Phase 1	Locked · track to reveal	OngoingActive, not recruiting	130 est.	22 Jan 2027
A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a)NCT07645248HFA-152a	Phase 3	Not yet scored	OngoingNot yet recruiting	110 est.	25 Feb 2027
A Study to Compare the Relative Potency of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152a to HFA-134a in Mild Asthmatics Aged 18 to 65 InclusiveNCT06433921Salbutamol HFA-152a	Phase 1	Locked · track to reveal	OngoingRecruiting	84 est.	26 Feb 2027
BALANCEA Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)NCT07519395Camlipixant	Phase 2	Locked · track to reveal	OngoingRecruiting	420 est.	9 Mar 2027
B-FocusStudy of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)NCT06497504Bepirovirsen	Phase 2	Locked · track to reveal	OngoingActive, not recruiting	153 est.	22 Apr 2027
A Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney DiseaseNCT06734234GSK4771261	Phase 1	Locked · track to reveal	OngoingActive, not recruiting	86 est.	23 Apr 2027
A Comparative Study to Investigate the Difference in Blood Levels of Two Different Formulations of GSK5784283NCT07712393GSK5784283	Phase 1	Not yet scored	OngoingNot yet recruiting	24 est.	30 Apr 2027
A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With BronchiectasisNCT07201051GSK3862995B	Phase 2	Locked · track to reveal	OngoingRecruiting	446 est.	4 May 2027
A Study to Investigate the Safety and PK of VH4770359 in Healthy ParticipantsNCT07525544VH4770359	Phase 1	Locked · track to reveal	OngoingRecruiting	214 est.	5 May 2027
B-UNITEDA Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)NCT06537414Daplusiran/Tomligisiran Dose Level 1	Phase 2	Locked · track to reveal	OngoingActive, not recruiting	283 est.	31 May 2027
A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)NCT06796907Mo-Rez	Phase 1	Locked · track to reveal	OngoingRecruiting	305 est.	21 Jun 2027
Efficacy and Safety of Depemokimab Monotherapy Without Concomitant Use of Intranasal Corticosteroids (INCS) in Japanese Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)NCT07701967Depemokimab	Phase 4	Not yet scored	OngoingNot yet recruiting	28 est.	1 Jul 2027
A Phase 2A Study of a Novel Antimalarial Pyrrolidinamide in Adult Patients With Uncomplicated P. Falciparum MalariaNCT07545681GSK3772701 600 mg	Phase 2	Locked · track to reveal	OngoingNot yet recruiting	70 est.	29 Jul 2027
A Study to Investigate the Difference In Blood Levels of Camlipixant Between Different Camlipixant Formulation PrototypesNCT07684586Camlipixant	Phase 1	Not yet scored	OngoingNot yet recruiting	28 est.	26 Aug 2027
CALM-2A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough - China ExtensionNCT07650084BLU-5937	Phase 3	Not yet scored	OngoingRecruiting	75 est.	27 Aug 2027
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid TumorsNCT05277051Remzistotug	Phase 1	Locked · track to reveal	OngoingActive, not recruiting	152 est.	31 Aug 2027
A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)NCT06431594Mocertatug rezetecan	Phase 1	Locked · track to reveal	OngoingRecruiting	675 est.	22 Sept 2027
A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate CancerNCT06990880GSK5458514	Phase 1	Locked · track to reveal	OngoingRecruiting	85 est.	26 Oct 2027
A Study to Evaluate the Safety, Reactogenicity, and Immune Response of the GSK Vaccines Institute for Global Health (GVGH) Quadrivalent Pan-Salmonella Vaccine With and Without Alum in Healthy Young AdultsNCT07663032Pan-Salmonella-with-Alum (Low dose) vaccine	Phase 1	Not yet scored	OngoingNot yet recruiting	196 est.	14 Nov 2027
A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)NCT07602777Ris-Rez	Phase 1	Locked · track to reveal	OngoingRecruiting	113 est.	18 Nov 2027
A Study of Velzatinib in Participants With Metastatic and/or Unresectable GIST After Imatinib, Sunitinib, Regorafenib, and PimitespibNCT07689201Velzatinib	Phase 2	Not yet scored	OngoingNot yet recruiting	24 est.	13 Dec 2027
Depemokimab Asthma Imaging and Bronchoscopy Sub-StudyNCT06979323Depemokimab	Phase 3	Locked · track to reveal	OngoingRecruiting	150 est.	5 Jan 2028
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically RemovedNCT06885034GSK5764227	Phase 1	Locked · track to reveal	OngoingRecruiting	451 est.	10 Jan 2028
A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD ParticipantsNCT06576271GSK4527363	Phase 1	Locked · track to reveal	OngoingRecruiting	142 est.	11 Jan 2028
First Time in Human Study of Long Acting VH4524184 FormulationsNCT06310551Oral VH4524184	Phase 1	Locked · track to reveal	OngoingRecruiting	372 est.	21 Jan 2028
A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of AgeNCT07406360MMRVNS	Phase 3	Locked · track to reveal	OngoingRecruiting	1,209 est.	28 Feb 2028
A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)NCT07286331Mocertatug rezetecan	Phase 3	Locked · track to reveal	OngoingRecruiting	600 est.	29 Feb 2028
ELEVATE-1A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)NCT07371468GSK5926371	Phase 1	Locked · track to reveal	OngoingRecruiting	44 est.	15 Mar 2028
First-Time-in-Human Study of GSK5471713 in Adults With mCRPCNCT07332455GSK5471713	Phase 1	Locked · track to reveal	OngoingRecruiting	54 est.	24 Mar 2028
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib TherapyNCT07218926IDRX-42	Phase 3	Locked · track to reveal	OngoingRecruiting	450 est.	30 May 2028
A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASHNCT06920043Efimosfermin	Phase 2	Locked · track to reveal	OngoingRecruiting	42 est.	10 Jul 2028
DREAMM-20A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination TreatmentsNCT05714839Unconjugated belantamab antibody	Phase 1	Locked · track to reveal	OngoingRecruiting	123 est.	3 Aug 2028
A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid TumorsNCT07213609GSK5460025	Phase 1	Locked · track to reveal	OngoingRecruiting	47 est.	28 Sept 2028
A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose Primary Dosing Series Followed by a Booster Dose at 12 to 15 Months of AgeNCT07406347Pn-MAPS30plus	Phase 1	Locked · track to reveal	OngoingNot yet recruiting	60 est.	18 Oct 2028
B-SureLong-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)NCT04954859Bepirovirsen	Phase 2	Locked · track to reveal	OngoingActive, not recruiting	360 est.	24 Jan 2029
DREAMM-16Study of Alternative and Approved Dosing Regimens of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Relapsed/Refractory Multiple MyelomaNCT07614360Belantamab mafodotin	Phase 2	Locked · track to reveal	OngoingNot yet recruiting	150 est.	28 Feb 2029
GLIDEA Study of Depemokimab in Participants of 6 to 11 Years of AgeNCT07671001Depemokimab	Phase 3	Not yet scored	OngoingNot yet recruiting	30 est.	19 Mar 2029

View all trials3,989

A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202

Phase 2Active, not recruitingNCT06062420 ↗

Primary completion: Sept 2026; estimated
Enrollment: 316; estimated
Start: Nov 2023; GlaxoSmithKline

Conditions

Neoplasms, Head and Neck

Interventions

Dostarlimab
Belrestotug
Nelistotug
Remzistotug

Brief summary

The primary purpose of the study is to evaluate the antitumor activity and safety of novel immunotherapy combinations compared with dostarlimab in participants with Programmed death ligand 1 (PD-L1) positive Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC).

Full record on ClinicalTrials.gov ↗

Change timeline

7 recorded · latest 1 May 2026

Completion date move · 4

Status change · 2

Enrollment change · 1

Track GSK drugs to see every change the night it lands.

Track pembrolizumab

A Study to Assess the Safety and Pharmacokinetics of a Human Monoclonal Antibody (VH4527079) in Healthy Adults and Persons With HIV

Phase 1Active, not recruitingNCT06652958 ↗

Primary completion: Sept 2026; estimated
Enrollment: 102; estimated
Start: Oct 2024; ViiV Healthcare

Conditions

HIV Infections

Interventions

VH4527079

Brief summary

This study evaluates the safety, tolerability, and pharmacokinetics (PK) of a single dose administration of VH4527079 by subcutaneous (SC) injection or by intravenous (IV) infusion in healthy adult participants and multiple dose administration by IV infusion in healthy adult participants and in Persons with HIV (PWH).

Full record on ClinicalTrials.gov ↗

Change timeline

5 recorded · latest 1 Apr 2026

Status change · 2

Completion date move · 2

Enrollment change · 1

Track GSK drugs to see every change the night it lands.

Track pembrolizumab

OCEAN: Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)

Phase 3Active, not recruitingNCT05263934 ↗

Primary completion: Sept 2026; estimated
Enrollment: 163; estimated
Start: Jul 2022; GlaxoSmithKline

Conditions

Eosinophilic Granulomatosis With Polyangiitis

Interventions

Depemokimab
Mepolizumab
Placebo matching mepolizumab
Placebo matching depemokimab

Brief summary

This study aims to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with relapsing or refractory EGPA receiving SoC therapy.

Full record on ClinicalTrials.gov ↗

Change timeline

5 recorded · latest 1 Dec 2025

Status change · 2

Completion date move · 2

Enrollment change · 1

Track GSK drugs to see every change the night it lands.

Track pembrolizumab

A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

Phase 2Active, not recruitingNCT05565378 ↗

Primary completion: Nov 2026; estimated
Enrollment: 351; estimated
Start: Oct 2022; GlaxoSmithKline

Conditions

Lung Cancer, Non-Small Cell

Interventions

Pembrolizumab
Dostarlimab
Belrestotug
Nelistotug

Brief summary

This study will monitor the safety of novel immunotherapy combinations in participants with Programmed death ligand-1 (PD L-1) high (Tumor cells \[TC\]/ Tumor proportion score \[TPS\] \>= 50%), previously untreated, unresectable, locally advanced or metastatic non-small cell lung cancer (NSCLC). Drug name mentioned as…

Full record on ClinicalTrials.gov ↗

Change timeline

5 recorded · latest 1 Sept 2025

Completion date move · 3

Enrollment change · 1

Status change · 1

Track GSK drugs to see every change the night it lands.

Track pembrolizumab

A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults

Phase 1RecruitingNCT07464314 ↗

Primary completion: Dec 2026; estimated
Enrollment: 225; estimated
Start: Mar 2026; GlaxoSmithKline

Conditions

Influenza, Human+COVID-19

Interventions

Investigational mRNA Seasonal Flu/COVID-19 Combination (Flu/COVm) Vaccine
Licensed Seasonal Influenza Vaccine
Licensed COVID-19 Vaccine

Brief summary

This early-stage study will look at a new mRNA vaccine that combines defenses against both seasonal flu and COVID-19 in terms of its safety and how it builds protection. Healthy adults aged 65 to 85 will receive different doses of this new vaccine, a standard flu vaccine, or COVID-19 vaccine. The study will assess any…

Full record on ClinicalTrials.gov ↗

Change timeline

No changes recorded on this trial in the observed window.

Extended Access of Momelotinib in Adults With Myelofibrosis

Phase 2Active, not recruitingNCT03441113 ↗

Primary completion: Dec 2026; estimated
Enrollment: 237; estimated
Start: May 2018; GlaxoSmithKline

Conditions

Neoplasms
Post-polycythemia Vera Myelofibrosis (Post-PV MF)
Primary Myelofibrosis (PMF)
Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
Primary Myelofibrosis

Interventions

Brief summary

The primary objective of this study is to provide extended access and assess long-term safety of momelotinib (MMB) in participants with primary myelofibrosis (PMF) or post-polycythemia vera or post-essential thrombocythemia myelofibrosis (Post-PV/ET MF) enrolled in studies GS-US-352-0101 (NCT01969838), GS-US-352-1214…

Full record on ClinicalTrials.gov ↗

Change timeline

2 recorded · latest 1 Oct 2023

Enrollment change · 1

Status change · 1

Track GSK drugs to see every change the night it lands.

Track pembrolizumab

A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study

Phase 2RecruitingNCT04641247 ↗

Primary completion: Dec 2026; estimated
Enrollment: 37; estimated
Start: Apr 2021; GlaxoSmithKline

Conditions

Ovarian Neoplasms
Breast Neoplasms

Interventions

Niraparib

Brief summary

This is a global extension study to provide continued access to niraparib and further characterize the long-term safety of niraparib treatment in participants who are currently receiving treatment with niraparib within GlaxoSmithKline/TESARO-sponsored studies (NCT01847274, NCT02354586, NCT01905592, NCT03308942,…

Full record on ClinicalTrials.gov ↗

Change timeline

6 recorded · latest 1 Oct 2025

Completion date move · 2

Enrollment change · 2

Status change · 2

Track GSK drugs to see every change the night it lands.

Track pembrolizumab

ENTRANCE: A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV

Phase 1Active, not recruitingNCT07053384 ↗

Primary completion: Jan 2027; estimated
Enrollment: 130; estimated
Start: Jul 2025; ViiV Healthcare

Conditions

HIV Infections

Interventions

VH3810109
Fostemsavir (FTR)
SOC INSTI-based ART

Brief summary

This study investigates the use of VH3810109 with or without FTR to reduce the size and activity of the HIV viral reservoir in two sub-populations of people living with HIV: treatment-naïve adults (Population 1) and treatment-experienced adults currently taking a standard of care (SOC) integrase strand transfer…

Full record on ClinicalTrials.gov ↗

Change timeline

4 recorded · latest 1 Apr 2026

Status change · 2

Enrollment change · 1

Completion date move · 1

Track GSK drugs to see every change the night it lands.

Track pembrolizumab

A Study to Compare the Relative Potency of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152a to HFA-134a in Mild Asthmatics Aged 18 to 65 Inclusive

Phase 1RecruitingNCT06433921 ↗

Primary completion: Feb 2027; estimated
Enrollment: 84; estimated
Start: Aug 2024; GlaxoSmithKline

Conditions

Asthma
Mild Asthma

Interventions

Salbutamol HFA-152a
Salbutamol HFA-134a
Placebo

Brief summary

The primary objectives of the study are: Part 1: to characterize the potency and variability of dose response on efficacy (Provocative concentration of methacholine causing at least a 20% fall in forced expiratory volume (FEV1) \[PC20\]) of salbutamol administered via MDI with salbutamol HFA-134a or salbutamol…

Full record on ClinicalTrials.gov ↗

Change timeline

4 recorded · latest 1 Nov 2025

Completion date move · 3

Status change · 1

Track GSK drugs to see every change the night it lands.

Track pembrolizumab

A Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease

Phase 1Active, not recruitingNCT06734234 ↗

Primary completion: Apr 2027; estimated
Enrollment: 86; estimated
Start: Dec 2024; GlaxoSmithKline

Conditions

Kidney Disease

Interventions

GSK4771261
Placebo matching GSK4771261

Brief summary

This is a study where a new drug, called GSK4771261 is being tested. Neither the study doctors, study staff or participants will be aware of what treatment is being given. Part A is testing the new study treatment on healthy people. This is to see if it's safe, what it does to the body, and how the body's defense…

Full record on ClinicalTrials.gov ↗

Change timeline

2 recorded · latest 1 Aug 2025

Completion date move · 1

Status change · 1

Track GSK drugs to see every change the night it lands.

Track pembrolizumab

B-UNITED: A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)

Phase 2Active, not recruitingNCT06537414 ↗

Primary completion: May 2027; estimated
Enrollment: 283; estimated
Start: Nov 2024; GlaxoSmithKline

Conditions

Chronic Hepatitis B Virus Infection
Hepatitis B

Interventions

Daplusiran/Tomligisiran Dose Level 1
Daplusiran/Tomligisiran Dose Level 2
Bepirovirsen
Placebo

Brief summary

The study is intended to evaluate the efficacy and safety of 2 different doses of DAP/TOM followed by bepirovirsen in participants living with CHB on standard of care nucleos(t)ide analogue (NA) therapy. The study also aims to identify an optimal dose of DAP/TOM for sequenced therapy with bepirovirsen for further…

Full record on ClinicalTrials.gov ↗

Change timeline

6 recorded · latest 1 Aug 2025

Completion date move · 3

Status change · 2

Enrollment change · 1

Track GSK drugs to see every change the night it lands.

Track pembrolizumab

A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)

Phase 1RecruitingNCT06796907 ↗

Primary completion: Jun 2027; estimated
Enrollment: 305; estimated
Start: Mar 2025; GlaxoSmithKline

Conditions

Tumours, Gynecological

Interventions

Mo-Rez
Dostarlimab
Bevacizumab

Brief summary

Advanced solid tumors are cancers that have spread to other parts of the body. While many treatments exist, most people become resistant to them, and the cancer returns. Researchers are developing new treatments that combine different medicines for those who do not respond to single medicine. This study is looking at…

Full record on ClinicalTrials.gov ↗

Change timeline

3 recorded · latest 1 Jun 2026

Completion date move · 2

Enrollment change · 1

Track GSK drugs to see every change the night it lands.

Track pembrolizumab

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

Phase 1Active, not recruitingNCT05277051 ↗

Primary completion: Aug 2027; estimated
Enrollment: 152; estimated
Start: Mar 2022; GlaxoSmithKline

Conditions

Neoplasms

Interventions

Remzistotug
Dostarlimab
Belrestotug
Nelistotug
GSK5764227

Brief summary

This is a first time in-human (FTIH) study designed to investigate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of remzistotug in participants with select loco-regionally recurrent solid tumors or metastatic solid tumors where curative or standard treatment options have been exhausted.

Full record on ClinicalTrials.gov ↗

Change timeline

8 recorded · latest 1 Apr 2026

Completion date move · 5

Enrollment change · 2

Status change · 1

Track GSK drugs to see every change the night it lands.

Track pembrolizumab

A Study to Evaluate the Safety, Reactogenicity, and Immune Response of the GSK Vaccines Institute for Global Health (GVGH) Quadrivalent Pan-Salmonella Vaccine With and Without Alum in Healthy Young Adults

Phase 1Not yet recruitingNCT07663032 ↗

Primary completion: Nov 2027; estimated
Enrollment: 196; estimated
Start: Jun 2026; GlaxoSmithKline

Conditions

Salmonella Infections

Interventions

Pan-Salmonella-with-Alum (Low dose) vaccine
Pan-Salmonella-with-Alum (Full dose) vaccine
Pan-Salmonella-without-Alum (Low dose) vaccine
Pan-Salmonella-without-Alum (Full dose) vaccine
Typhoid Vi conjugate vaccine
Placebo

Brief summary

The current clinical study will evaluate the GVGH Quadrivalent Pan-Salmonella vaccine for the first time in healthy adults in Africa. The purpose of the current Phase 1 study is to evaluate the safety, reactogenicity, and the immune response induced by the Pan-Salmonella vaccine.

Full record on ClinicalTrials.gov ↗

Change timeline

No changes recorded on this trial in the observed window.

A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed

Phase 1RecruitingNCT06885034 ↗

Primary completion: Jan 2028; estimated
Enrollment: 451; estimated
Start: Jun 2025; GlaxoSmithKline

Conditions

Gastrointestinal Neoplasms

Interventions

GSK5764227

Brief summary

This study will check how well a new medicine, GSK5764227, works, how safe it is and how the body handles it in participants all around the world with advanced inoperable or metastatic gastrointestinal cancer who have previously received treatment.

Full record on ClinicalTrials.gov ↗

Change timeline

4 recorded · latest 1 Sept 2025

Enrollment change · 2

Completion date move · 1

Status change · 1

Track GSK drugs to see every change the night it lands.

Track pembrolizumab

A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants

Phase 1RecruitingNCT06576271 ↗

Primary completion: Jan 2028; estimated
Enrollment: 142; estimated
Start: Sept 2024; GlaxoSmithKline

Conditions

Systemic Lupus Erythematosus

Interventions

GSK4527363
Placebo matching GSK4527363
Belimumab

Brief summary

This study will assess the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of GSK4527363 in healthy participants (Part A), participants with active SLE (Part B), healthy participants of Chinese and Japanese descent (Part C), and participants with interstitial lung disease associated with…

Full record on ClinicalTrials.gov ↗

Change timeline

4 recorded · latest 1 Jan 2026

Completion date move · 2

Enrollment change · 1

Status change · 1

Track GSK drugs to see every change the night it lands.

Track pembrolizumab

First Time in Human Study of Long Acting VH4524184 Formulations

Phase 1RecruitingNCT06310551 ↗

Primary completion: Jan 2028; estimated
Enrollment: 372; estimated
Start: Mar 2024; ViiV Healthcare

Conditions

HIV Infections

Interventions

Oral VH4524184
VH4524184 Formulation A SC
Placebo Formulation A SC
rHuPH20
VH4524184 Formulation B SC
Placebo Formulation B SC
VH4524184 Formulation A IM
Placebo Formulation A IM

Brief summary

The purpose of this study is to identify 1 or more doses of parenterally administered VH4524184 that are safe, well tolerated and yield a PK drug exposure profile necessary to deliver a long-acting antiretroviral therapy for the treatment of HIV-1 infection.

Full record on ClinicalTrials.gov ↗

Change timeline

4 recorded · latest 1 Apr 2026

Completion date move · 2

Enrollment change · 1

Status change · 1

Track GSK drugs to see every change the night it lands.

Track pembrolizumab

A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age

Phase 3RecruitingNCT07406360 ↗

Primary completion: Feb 2028; estimated
Enrollment: 1,209; estimated
Start: May 2026; GlaxoSmithKline

Conditions

Measles
Measles-Mumps-Rubella+Chickenpox Vaccine

Interventions

MMRVNS
MMRV

Brief summary

This study is evaluating the immunogenicity and safety of intramuscular administration of the investigational MMRVNS vaccine compared to intramuscular administration of the MMRV (Merck's measles, mumps, rubella and varicella) vaccine (ProQuad) that is already licensed for this route, when administered as a second dose…

Full record on ClinicalTrials.gov ↗

Change timeline

No changes recorded on this trial in the observed window.

A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)

Phase 3RecruitingNCT07286331 ↗

Primary completion: Feb 2028; estimated
Enrollment: 600; estimated
Start: Jun 2026; GlaxoSmithKline

Conditions

Neoplasms, Endometrial

Interventions

Mocertatug rezetecan
Paclitaxel
Doxorubicin

Brief summary

This study specifically aims to evaluate how well mocertatug rezetecan (Mo-Rez) works in treating Endometrial Cancer (EC) compared to standard of care. The study also assesses whether Mo-Rez is safe and tolerated well by participants in comparison to standard of care and will help provide a better understanding of the…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Apr 2026

Completion date move · 1

Track GSK drugs to see every change the night it lands.

Track pembrolizumab

A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy

Phase 3RecruitingNCT07218926 ↗

Primary completion: May 2028; estimated
Enrollment: 450; estimated
Start: Dec 2025; GlaxoSmithKline

Conditions

Gastrointestinal Neoplasms

Interventions

IDRX-42
Sunitinib

Brief summary

The purpose of this study is to find out if a new drug, called IDRX-42 (also known as GSK6042981), is effective in treating adults with a type of cancer called Gastrointestinal Stromal Tumors (GIST) when compared to another drug named sunitinib. The study will see if IDRX-42 works well and is safe for participants…

Full record on ClinicalTrials.gov ↗

Change timeline

2 recorded · latest 1 Jan 2026

Status change · 1

Completion date move · 1

Track GSK drugs to see every change the night it lands.

Track pembrolizumab

DREAMM-20: A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments

Phase 1RecruitingNCT05714839 ↗

Primary completion: Aug 2028; estimated
Enrollment: 123; estimated
Start: Jun 2023; GlaxoSmithKline

Conditions

Multiple Myeloma

Interventions

Unconjugated belantamab antibody
Belantamab mafodotin
Unconjugated belantamab antibody and belantamab mafodotin
Unconjugated belantamab antibody in combination with pomalidomide-dexamethasone backbone

Brief summary

The study consists of three parts: Part 1 The primary purpose of this part aims to evaluate the safety, tolerability, and clinical activity of escalating doses of single agent Unconjugated belantamab antibody in participants with refractory multiple myeloma (RRMM) who have received at least 3 prior therapies (4L+).…

Full record on ClinicalTrials.gov ↗

Change timeline

6 recorded · latest 1 Feb 2026

Completion date move · 3

Enrollment change · 2

Status change · 1

Track GSK drugs to see every change the night it lands.

Track pembrolizumab

B-Sure: Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)

Phase 2Active, not recruitingNCT04954859 ↗

Primary completion: Jan 2029; estimated
Enrollment: 360; estimated
Start: Dec 2021; GlaxoSmithKline

Conditions

Hepatitis B

Interventions

Bepirovirsen
Placebo

Brief summary

This is a global multi-center, long-term follow-up study to assess durability of efficacy, as measured by maintenance of treatment response from the parent study, in participants who participated in a previous bepirovirsen study and achieved a complete or partial response. Eligible participants will be enrolled in…

Full record on ClinicalTrials.gov ↗

Change timeline

4 recorded · latest 1 Oct 2024

Completion date move · 4

Track GSK drugs to see every change the night it lands.

Track pembrolizumab

DREAMM-16: Study of Alternative and Approved Dosing Regimens of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Relapsed/Refractory Multiple Myeloma

Phase 2Not yet recruitingNCT07614360 ↗

Primary completion: Feb 2029; estimated
Enrollment: 150; estimated
Start: Aug 2026; GlaxoSmithKline

Conditions

Multiple Myeloma

Interventions

Belantamab mafodotin
Dexamethasone
Bortezomib

Brief summary

The aim of this study is to assess safety, efficacy and pharmacokinetic (PK) parameters with alternative dosing schedules of belantamab mafodotin in combination with bortezomib and dexamethasone compared to the approved dosing regimen in participants with relapsed or refractory multiple myeloma (RRMM) who have…

Full record on ClinicalTrials.gov ↗

Change timeline

No changes recorded on this trial in the observed window.